The UK NICE, in partnership with the National Collaborating Centre for Primary Care (NCC PC), has issued new guidance to the NHS in England and Wales on the identification of individuals at risk for cardiovascular disease (CVD), and on the use of lipid-lowering drugs to reduce that risk. ...
1.2Aspirinforprimaryprevetionof cardiovasculardisease 1.2.1DonotroutinelyofferaspirinforprimarypreventionofCVD.[January2023] Forguidanceonusingaspirintopreventvenousthromboembolisminover16sin hospital,seeNICEsguidelineonvenousthromboembolisminover16s:reducing theriskofhospital-acquireddeepveinthrombosisorpulmonaryembolism...
tyofmoderate-intensitystatinwithezetimibecombinationtherapyve rsushigh-intensitystatinmonotherapyinpatientswithatherosclerot iccardiovasculardisease(RACING):arandomised,open-label,non -inferioritytrial[J].Lancet,2022,00(1039):380-390.DOI:1 0.1016/S010-6736(22)00916-3. [25]PreissD,SeshasaiSR,WelshP,etal...
Anupdate of existing National Institute for Health and CareExcellence (NICE) guidance (published in 2008)1 was necessaryin light of new evidence on the efficacy and safety of statintherapy,2on the effects of combining statins with non-statindrugs,3-5and on novel risk assessment tools for ...
The NICE guidance specifically recommends that GPs start statin treatment for the primary prevention of CVD with atorvastatin 20mg while patients with established CVD, type 1 diabetes or type 2 diabetes should be offered a higher strength 80mg dose of atorvastatin. However, NICE also acknowledges not...
The article discusses the recommendations and implications of the updated guidance on cardiovascular risk assessment and blood lipids modification released by the National Institute for Health and Care Excellence (NICE). Topics discussed include the use of QRISK2 as cardiovascular risk assessment to preve...
The appraisal assessed evolocumab as monotherapy or in combination with a statin with or without ezetimibe, or in combination with ezetimibe (without statin therapy), in adult patients with primary hypercholesterolaemia (which includes mixed dyslipidaemia), for whom statins do not provide optimal ...
NICE《心血管疾病风险评估与降低,包括脂质调节》指南 2023 年新增部分解读 .pdf,本文对由英国国家卫生与临床优化研究所NICE2023年发布的《心血管疾病风险评估与降低,包括脂质调节》指南进行解读,并对新增部分进行了解读主要关注的是通过风险评估工具来了解心血管疾病一级
Statin therapy for the primary prevention of cardiovascular disease(CVD)has been recommended by the National Institute for Health and Clinical Excellence for adults who have a 20 per cent or greater 10-year risk of developing CVD.Guidance published this week also recommends statins for adults with ...
The recently issued guidance from the National Institute for Health and Clinical Excellence (NICE)1 on the cholesterol absorption inhibitor ezetimibe is welcome and summarised in this issue of Heart.2 NICE recommends its use in combination with a statin when more intensive low-density lipoprotein (...